Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?

Michele Romoli, Cinzia Costa, Sabrina Siliquini, Ilenia Corbelli, Paolo Eusebi, Chiara Bedetti, Stefano Caproni, Letizia Maria Cupini, Paolo Calabresi, Paola Sarchielli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)


Background: The impact of adverse events (AEs) of antiepileptic drugs (AEDs) have an impact on compliance and dropouts. We compared tolerability of AEs of AEDs among patients with migraine, epilepsy, or both. Methods: Overall, 335 patients (epilepsy (n = 142), migraine (n = 131), and both (n = 62)), were evaluated with the Liverpool Adverse Events Profile (LAEP) to assess the magnitude, profile and occurrence rate of the AEs of valproate, topiramate, and lamotrigine. Results: AEs were significantly more common with topiramate treatment (71.0%) and among migraineurs (69.5%), the latter being more prone to discontinue AEDs (46.6%). The profile of AEs with topiramate and valproate differed among groups. Moreover, treatment with both topiramate and valproate was associated, for all groups, with a worse tolerability profile compared to lamotrigine. Conclusion: Our data suggest a specific drug and disease AE profile of AEDs. Specifically, migraineurs are the most affected by AEs, even though they receive very low dosages of AEDs. This finding might be considered a clinical implication of central sensitization mechanisms. Both the profile and tolerability of AEs, highly influencing quality of life, depended on the underlying conditions, and deeply impacted on treatment dropout. Therefore, before starting, switching or stopping AED treatment, all options need to be considered.
Lingua originaleEnglish
pagine (da-a)274-282
Numero di pagine9
Stato di pubblicazionePubblicato - 2018


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticonvulsants
  • Child
  • Epilepsy
  • Female
  • Humans
  • Lamotrigine
  • Male
  • Middle Aged
  • Migraine Disorders
  • Tolerability
  • Topiramate
  • Valproic Acid
  • Young Adult
  • adverse events
  • antiepileptic drugs
  • epilepsy
  • migraine
  • neuropharmacology


Entra nei temi di ricerca di 'Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?'. Insieme formano una fingerprint unica.

Cita questo